These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6938021)

  • 1. Cyclophosphamide-prednisolone therapy in advanced prostatic carcinoma.
    Andersson L; Edsmyr F; Esposti PL; Hedlund PO; Rönström L
    Scand J Urol Nephrol Suppl; 1980; 55():169-71. PubMed ID: 6938021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Palliative chemotherapy with 5 FU and CPM in cancer of the prostate with bone metastases resistant to oestrogens. A clinical trial (author's transl)].
    Kuss R; Khoury S; Richard F; Fourcade R; Frantz P; Capelle JP
    J Urol Nephrol (Paris); 1979; 85(10-11):649-55. PubMed ID: 94108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytostatic therapy of prostatic carcinoma. Current status and personal results].
    Nagel R; Leistenschneider W
    Urologe A; 1983 Sep; 22 Suppl():304-9. PubMed ID: 6356555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Estrogen-resistant prostatic cancer with bone metastases: palliative chemotherapy with 5-fluorouracil and cyclophosphamide].
    Küss R; Khoury S; Richard F; Fourcade R; Frantz P; Capelle JP
    Nouv Presse Med; 1978 Aug 26-Sep 2; 7(28):2478-9. PubMed ID: 80785
    [No Abstract]   [Full Text] [Related]  

  • 6. Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate.
    Edsmyr F; Esposti PL; Andersson L
    Scand J Urol Nephrol Suppl; 1980; 55():139-42. PubMed ID: 6938017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy of advanced prostate cancer].
    Murphy GP
    Vopr Onkol; 1977; 23(12):26-38. PubMed ID: 146305
    [No Abstract]   [Full Text] [Related]  

  • 8. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
    Eagan RT; Hahn RG; Myers RP
    Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment with prednisolone of hormone-refractory prostate cancer.
    Fuse H; Nozaki T; Fujiuchi Y; Mizuno I; Nagakawa O; Okumura A
    Arch Androl; 2006; 52(1):35-8. PubMed ID: 16338867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
    Datta SN; Thomas K; Matthews PN
    J Urol; 1997 Jul; 158(1):175-7. PubMed ID: 9186348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse relationship between serum cholinesterase activity and the administration of cyclophosphamide: an index of cyclophosphamide therapy.
    Imai H; Kodama T; Yasuda T; Nakamoto Y; Miura AB
    Nephrol Dial Transplant; 1994; 9(9):1240-9. PubMed ID: 7816283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide.
    Germá Lluch JR; Marcuello Gaspar E; de Andrés Basauri L; López Pousa A; López López JJ
    Rev Esp Oncol; 1982; 29(2):317-24. PubMed ID: 7188232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of a high-dose regimen of cyclophosphamide and prednisolone in advanced non-Hodgkin's lymphoma of favorable histologic type.
    Bell R; Gallagher CJ; Ford J; Malpas JS; Lister TA
    Cancer Treat Rep; 1982 Feb; 66(2):377-80. PubMed ID: 7055819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypophysectomy in the advanced stage of carcinoma of the prostate (author's transl)].
    Klosterhalfen H; Becker H; Lotzin C; Kautzky R
    Urologe A; 1980 Mar; 19(2):85-8. PubMed ID: 6157241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
    Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R
    Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of advanced prostatic carcinoma.
    Lukkarinen O; Lehikoinen K
    Ann Chir Gynaecol Suppl; 1993; 206():9-13. PubMed ID: 8291878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
    Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer.
    Seski JC; Edwards CL; Gershenson DM; Copeland LJ
    Obstet Gynecol; 1981 Jul; 58(1):88-91. PubMed ID: 7195533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
    Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
    J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
    Drago JR; Worgul TJ
    Invest Urol; 1981 Nov; 19(3):191-3. PubMed ID: 7298290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.